New published study with exciting preclinical results about the second generation RET inhibitor vepafestinib (TAS0953/HM06).
Vepafestinib showed selectivity against most common RET resistance mutations including the RETG810 mutation, and superior pharmacokinetic properties in the brain. The compound showed activity in an intracranial model of RET-driven cancer. The compound is currently being tested clinically in a phase 1-2 study (https://clinicaltrials.gov/study/NCT04683250).
https://pubmed.ncbi.nlm.nih.gov/37743366/